Secondary cytoreduction followed by chemotherapy versus chemotherapy alone in platinum-sensitive relapsed ovarian cancer (SOC-1): a multicentre, open-label, randomised, phase 3 trial
Published 2021 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Secondary cytoreduction followed by chemotherapy versus chemotherapy alone in platinum-sensitive relapsed ovarian cancer (SOC-1): a multicentre, open-label, randomised, phase 3 trial
Authors
Keywords
-
Journal
LANCET ONCOLOGY
Volume -, Issue -, Pages -
Publisher
Elsevier BV
Online
2021-03-09
DOI
10.1016/s1470-2045(21)00006-1
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- OVARIAN CANCER RELAPSE: FROM THE LATEST SCIENTIFIC EVIDENCE TO THE BEST PRACTICE
- (2019) Daniela Luvero et al. CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY
- Relapsed ovarian cancer - diagnosis using 18F-FDG PET/CT; 4.
- (2019) Fabio Peroba Esteves et al. Revista da Associacao Medica Brasileira
- Treatment-Free Survival: A Novel Outcome Measure of the Effects of Immune Checkpoint Inhibition—A Pooled Analysis of Patients With Advanced Melanoma
- (2019) Meredith M. Regan et al. JOURNAL OF CLINICAL ONCOLOGY
- Secondary Surgical Cytoreduction for Recurrent Ovarian Cancer
- (2019) Robert L. Coleman et al. NEW ENGLAND JOURNAL OF MEDICINE
- A comparative analysis of prediction models for complete gross resection in secondary cytoreductive surgery for ovarian cancer
- (2017) Renee A. Cowan et al. GYNECOLOGIC ONCOLOGY
- Bevacizumab and paclitaxel–carboplatin chemotherapy and secondary cytoreduction in recurrent, platinum-sensitive ovarian cancer (NRG Oncology/Gynecologic Oncology Group study GOG-0213): a multicentre, open-label, randomised, phase 3 trial
- (2017) Robert L Coleman et al. LANCET ONCOLOGY
- The role of F18-FDG PET/CT in predicting secondary optimal de-bulking in patients with recurrent ovarian cancer
- (2017) Amnon Amit et al. SURGICAL ONCOLOGY-OXFORD
- Early initiation of chemotherapy following complete resection of advanced ovarian cancer associated with improved survival: NRG Oncology/Gynecologic Oncology Group study
- (2015) K. S. Tewari et al. ANNALS OF ONCOLOGY
- Intermediate clinical endpoints: A bridge between progression-free survival and overall survival in ovarian cancer trials
- (2014) Ursula A. Matulonis et al. CANCER
- Ovarian cancer clinical trial endpoints: Society of Gynecologic Oncology white paper
- (2013) Thomas J. Herzog et al. GYNECOLOGIC ONCOLOGY
- A Risk Model for Secondary Cytoreductive Surgery in Recurrent Ovarian Cancer: An Evidence-Based Proposal for Patient Selection
- (2011) Wen-Juan Tian et al. ANNALS OF SURGICAL ONCOLOGY
- Predictors of survival in patients with recurrent ovarian cancer undergoing secondary cytoreductive surgery based on the pooled analysis of an international collaborative cohort
- (2011) R Y Zang et al. BRITISH JOURNAL OF CANCER
- Definitions for Response and Progression in Ovarian Cancer Clinical Trials Incorporating RECIST 1.1 and CA 125 Agreed by the Gynecological Cancer Intergroup (GCIG)
- (2011) Gordon John Sampson Rustin et al. INTERNATIONAL JOURNAL OF GYNECOLOGICAL CANCER
- The National Cancer Database report on advanced-stage epithelial ovarian cancer: Impact of hospital surgical case volume on overall survival and surgical treatment paradigm
- (2010) Robert E. Bristow et al. GYNECOLOGIC ONCOLOGY
- Quality Improvement in the Surgical Approach to Advanced Ovarian Cancer: The Mayo Clinic Experience
- (2009) Giovanni D. Aletti et al. JOURNAL OF THE AMERICAN COLLEGE OF SURGEONS
Create your own webinar
Interested in hosting your own webinar? Check the schedule and propose your idea to the Peeref Content Team.
Create NowAsk a Question. Answer a Question.
Quickly pose questions to the entire community. Debate answers and get clarity on the most important issues facing researchers.
Get Started